Meningococcal Disease


     Meningococcal (muh-nin-jo-cok-ul) disease is a serious bacterial infection that most often leads to severe swelling of the tissues surrounding the brain and spinal cord (meningitis) or infection of the bloodstream (meningococcemia). Even with treatment, approximately one out of every 10 people who get meningococcal disease will die and of those who survive, up to 20 percent will suffer serious and permanent complications including brain damage, kidney damage, hearing loss, and amputation of arms, legs, fingers, or toes.

 NFID is committed to increasing awareness about meningococcal disease among consumers and healthcare professionals and to prevention of meningococcal disease through vaccination.

  • Routine vaccination with a quadrivalent vaccine that protects against four major meningococcal serogroups (A, C, W, and Y) is recommended for all adolescents at age 11-12 years with a booster dose at age 16 years. 

  • Meningococcal serogroup B vaccination may be recommended by healthcare professionals for certain individuals age 16-23 years, with a preferred age of 16-18 years. Learn more about serogroup B disease, vaccine insurance coverage, and recent outbreaks on US college campuses.

Talk to your healthcare professional to make sure that your child is fully protected against all serogroups of this deadly disease.

Learn more about meningococcal disease and the vaccines to prevent it in adolescents at adolescentvaccination.org and adults at adultvaccination.org.

View the Meningococcal Disease College Toolkit for resources to help increase awareness among the college community about the importance of meningococcal disease prevention.




July 2015

Resources

#NoRegrets

Public service announcement on the importance of getting vaccinated against both types of meningococcal disease

Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses

NFID report examining the public health response to the recent outbreaks and strategies for appropriate and streamlined public health responses to future outbreaks

Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on College Campuses (11/17/14 Webinar)

National Foundation for Infectious Diseases (NFID)

Adolescent Meningococcal Disease

adolescentvaccination.org

Adult Meningococcal Disease

adultvaccination.org

Beyond the Science: Putting a Face on Meningococcal Disease

National Meningitis Association

College Students and Meningococcal Disease: Are Students Protected? (8/2/16 Webinar)

National Foundation for Infectious Diseases (NFID)

Meningococcal Vaccination: Improving Rates in Adolescents

Call to Action discusses disparities, identifies barriers, and outlines strategies to increase meningococcal vaccination rates among all adolescents (June 2010)

Meningococcus Vaccine - Why Do College Students Need It?

A two-minute video from the Children's Hospital of Philadelphia Vaccine Education Center aimed at educating college students about the importance of getting a meningococcal vaccine. The video offers the perspective of a college student aiming to educate his peers.

Meningococcal Vaccines for Preteen and Teen Vaccines

Centers for Disease Control and Prevention

Meningococcal Disease

Centers for Disease Control and Prevention

Meningococcal Disease Information

Immunization Action Coalition

Meningitis

American Academy of Pediatrics (AAP)

Meningitis Foundation of America

Meningitis Information: Emergency Guidelines for the Campus Community

Princeton University

Meningitis Myths and Facts

National Foundation for Infectious Diseases (NFID)

Meningitis Research Foundation

Meningococcal B Questions & Answers

National Foundation for Infectious Disease (NFID)

Meningococcal Disease College Toolkit

National Foundation for Infectious Diseases (NFID)

Meningococcal Disease: Focus on Serogroup B

National Foundation for Infectious Diseases (NFID)

Meningococcal Serogroup ACWY Vaccine Information Statement

Centers for Disease Control and Prevention (CDC): Routine vaccination with a quadrivalent vaccine that protects against meningococcal serogroups A, C, W, and Y is recommended for all adolescents at age 11-12 years with a booster dose at age 16 years

Meningococcal Serogroup B Vaccine Information Statement

Centers for Disease Control and Prevention (CDC): Meningococcal serogroup B vaccination may be recommended by healthcare professionals for certain individuals age 16-23 years, with a preferred age of 16-18 years

Meningococcal Serogroup B Cases and Outbreaks on US College Campuses

Meningococcal Vaccination

Improving Rates in Adolescents and Reducing Racial, Ethnic, and Socioeconomic Disparities: NFID Call to Action (July 2010)

National Meningitis Association

Preteen and Teen Vaccines

Centers for Disease Control and Prevention (CDC)

Prevention and Control of Meningococcal Disease

Centers for Disease Control and Prevention (CDC): Recommendations of the Advisory Committee on Immunization Practices (March 2013)

Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Centers for Disease Control and Prevention

Sample Letter to Parents

This template letter can be personalized and mailed to families to educate them about meningococcal disease prevention and encourage parents to make an immunization appointment for adolescent children. (Updated July 2015)

Standing Orders and Meningococcal Vaccination Recommendations

Immunization Action Coalition (IAC): This document summarizes the CDC recommendations for the use of meningococcal vaccines and how to implement standing orders for administering meningococcal vaccine to children and teens.